Oslo, 12 August 2022 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
reliable provider of high-quality products to hospitals and pharmacies, grew
revenues by 67.2 percent in Q2 2022 compared to the same period in 2021 to NOK
110.4 million, driven by growth in the company's key business areas. Navamedic
reiterates its mid- to long-term ambition of building a NOK 1 billion company.

"We are pleased to report record-high revenues and continued strengthening of
our profits and cash flow in the second quarter. This was a result of strong
growth across several key  products, particularly the obesity drug Mysimba. We
have continued to progress well along our strategic path through the
strengthening of our existing portfolio by leveraging our strong market position
and by adding distribution and marketing rights for attractive products.
Furthermore, we have strengthened our platform through M&A with the acquisition
of Impolin," says Kathrine Gamborg Andreassen, CEO of Navamedic.

Navamedic's gross margin was 44.8 percent in Q2 2022, up from 39.3 percent in
the same period in 2021. EBITDA was NOK 23.7 million compared to NOK 4.3 million
in the second quarter of last year. Operating profit (EBIT) was NOK 21.9 million
compared to NOK 2.9 million in the same quarter in 2021.

"Even though the second quarter of 2022 was a great quarter for Navamedic, we
have only just started on our value creation journey. We are planning several
product launches in the months to come, and we have a good pipeline of potential
new distribution and marketing partnerships and acquisitions," says Gamborg
Andreassen.

In August 2022, Navamedic signed an agreement with Vectans Pharma, which gives
Navamedic the exclusive right to market and sell an innovative muco-adhesive
buccal tablet for single-dose treatment of cold sores in the Nordic and Benelux
regions.

"This is a great example of how we can utilize our strong presence and in-depth
competence in our markets to broaden our portfolio through partnerships with
international pharma companies. Navamedic has a competent and highly motivated
team and an excellent product portfolio, and the momentum we currently have
makes me confident that we will reach our mid-term revenue target of NOK 1
billion, including carefully selected acquisitions," says Gamborg Andreassen.

***

Navamedic will hold a presentation of the second quarter and first half 2022
financial results, Friday 12 August at 08.30 CET. The presentation will be held
at Haakon VIIs gate 2 in Oslo as well as via webcast on
www.navamedic.com/investors/financial-results. Representatives from Navamedic
will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached second quarter and first half 2022 presentation on slide 25.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic:

Navamedic ASA is a Nordic full-service provider of high-quality products to
hospitals and through pharmacies. Navamedic meets the specific needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation article 7 and is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock
exchange announcement was published by Lars Hjarrand at the time and date set
out above.